The Drug Story Behind Every Medicine: From Ambien to Wegovy – First Opinion Podcast Transcript with Thomas Goetz

When Thomas Goetz talked about his fresh podcast “Drug Story” on the First Opinion Podcast last week, he wasn’t just explaining another media project—he was describing how a single prescription drug can unravel entire narratives about American health, commerce, and culture. That idea stuck with me, especially when I thought about how those stories play out in neighborhoods like mine here in Chicago, where the South Side’s community health centers sit just blocks from world-class research institutions, and where conversations about medication access happen daily at places like the Harold Washington Library or over coffee at 95th and Dan Ryan.

Goetz, who launched his medical career at 69 and will begin residency at 72, brings a rare perspective to pharmaceutical storytelling. His podcast doesn’t just explain how drugs like Ambien or Ozempic operate—it investigates why they matter in unexpected ways. Take fluoride, for instance: as he noted in a recent episode, while the FDA classifies it as a drug and 75% of U.S. Water is fluoridated, many non-fluoridated countries show similar tooth decay rates to the U.S. That paradox—where a public health triumph meets modern skepticism—mirrors debates I’ve heard at Chicago Board of Health meetings and in PTA sessions at schools like Whitney Young.

The real power of Goetz’s approach lies in how he connects individual medications to broader societal patterns. When he discussed the EpiPen episode—born from years of misguided professional guidance on food allergies—it made me think about Chicago’s own allergy epidemic, particularly in neighborhoods where access to specialists at institutions like Lurie Children’s Hospital can vary dramatically by ZIP code. Similarly, his exploration of insomnia as a product of our “scrolling and alarms” culture feels painfully relevant when riding the CTA Red Line at 2 a.m. Or seeing shift workers rush to clinics near the Illinois Medical District.

What makes this locally urgent is how these drug stories intersect with Chicago’s specific healthcare landscape. The city’s unique position—as both a hub for pharmaceutical innovation (home to major research at Northwestern and the University of Chicago) and a place grappling with profound health disparities—creates a microcosm for the national trends Goetz examines. When he questions whether “Low T” is truly a disease, it echoes conversations I’ve had with clinicians at Cook County Health about how pharmaceutical marketing shapes diagnostic trends in communities already navigating complex social determinants of health.

Given my background in community health journalism, if these pharmaceutical narratives impact you in Chicago, here are the three types of local professionals you need to understand the full picture:

• Community Pharmacists with Public Health Training: Appear for professionals who work in neighborhood pharmacies—like those along Cicero Avenue or in Bronzeville—who don’t just dispense medication but actively participate in Chicago Department of Public Health outreach programs. The best ones can explain not only how a drug works but how local policies (like Illinois’ recent insulin price cap) affect access and adherence in specific communities.
• Medical Sociologists Affiliated with Chicago Academic Medical Centers: Seek researchers from places like Rush University Medical Center or the University of Illinois Chicago who study how cultural factors influence medication use. Prioritize those publishing work on Chicago-specific health behaviors—whether it’s examining statin adherence in South Side churches or analyzing antidepressant use patterns among CPS teachers—because their ground-level insights bridge the gap between national pharmaceutical trends and neighborhood realities.
• Health Policy Analysts Focused on Illinois Medicaid and 340B Programs: Find experts who deeply understand how federal pharmaceutical policies translate to local impact, particularly those affiliated with organizations like the Shriver Center on Poverty Law or the Illinois Public Health Institute. They should be able to trace how national drug pricing debates manifest in Chicago’s safety-net hospitals and community health centers, from Englewood to Uptown.

Ready to find trusted professionals? Browse our complete directory of top-rated first opinion,first opinion podcast,drug development,pharmaceuticals,public health experts in the Chicago area today.